Table A1.

Postrecurrence Survival of Patients in Previous Stage I NSCLC Series

Reference	Year of Publication	No. of Patients	Histologic Profile	Recurrence	Recurrence No. (%)	PRS		Independent Factors of Poor PRS
						Duration	%
Current study	2014	1,120	ADC: 1,120	ADC: 188	188 (17)	1-year	67	Solid predominant histologic pattern
					LR: 59 (31)	2-year	45	Sublobar resection
					D: 100 (53)	3-year	36	Old age
					LR + D: 29 (15)	5-year	14	Distant (extrathoracic) metastasis
Shimada et al10	2013	919	ADC: 706	ADC: 124	170 (18)	1-year	73	Male sex
			Non-ADC: 213	Non-ADC: 46	LR: 43 (25)	2-year	51	Non-postrecurrence therapy
					D: 113 (66)			Poorly differentiated
					LR + D: 14 (9)
Song et al11	2013	475	NSCLC	ADC: 46	72 (15)	1-year	88	Recurrence-free interval ≤ 12 months
				SCC: 15	LR: 36 (50)	3-year	53	Bad response for treatment
				Other: 11	D: 36 (50)
Nakagawa et al12	2008	397	ADC: 300	NA	87 (22)	1-year	67	Non-postrecurrence therapy (surgery); symptoms at recurrence: liver or cervico-mediastinum metastasis
			SCC: 89		LR: 30 (34.5)	3-year	35
			Other: 8		D: 57 (65.5)
Hung et al13	2009	933	NSCLC	ADC: 45	LR: 123 (13)	1-year	48	Non-postrecurrence therapy (surgery, chemotherapy, and/or radiotherapy)
				SCC: 60	LR: 74	2-year	19
				Other: 18	LR + D: 49
Hung et al14	2010	933	NSCLC	ADC: 95	D: 166 (18)	1-year	38	Non-postrecurrence therapy
				SCC: 46	Single: 106	2-year	19	Recurrence-free interval ≤ 16 months
				Other: 25	Multiple: 60
Hung et al9	2013	283	ADC: 283	ADC: 283	57 (20)	2-year	72.3	Solid predominant (P = .074; not significant); non-papillary predominant (P = .056; not significant)
						5-year	31.6

Abbreviations: ADC, adenocarcinoma; D, distant metastasis; LR, locoregional recurrence; NA, not applicable; NSCLC, non–small-cell lung cancer; PRS, postrecurrence survival; SCC, squamous cell carcinoma.